AR035807A1 - Composicion farmaceutica de liberacion modificada apropiada para compuestos antiarritmicos, procedimiento para su preparacion, y uso de esta composicion para la manufactura de un medicamento para ser usado en la profilaxis o tratamiento de una arritmia - Google Patents
Composicion farmaceutica de liberacion modificada apropiada para compuestos antiarritmicos, procedimiento para su preparacion, y uso de esta composicion para la manufactura de un medicamento para ser usado en la profilaxis o tratamiento de una arritmiaInfo
- Publication number
- AR035807A1 AR035807A1 ARP020101188A ARP020101188A AR035807A1 AR 035807 A1 AR035807 A1 AR 035807A1 AR P020101188 A ARP020101188 A AR P020101188A AR P020101188 A ARP020101188 A AR P020101188A AR 035807 A1 AR035807 A1 AR 035807A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- prophylaxis
- compounds
- procedure
- manufacture
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- KZOCHEDMAHPYCK-UHFFFAOYSA-N 4-[3-[3-(3,3-dimethyl-2-oxobutyl)-9-oxa-3,7-diazabicyclo[3.3.1]nonan-7-yl]propylamino]benzonitrile Chemical compound C1C(O2)CN(CC(=O)C(C)(C)C)CC2CN1CCCNC1=CC=C(C#N)C=C1 KZOCHEDMAHPYCK-UHFFFAOYSA-N 0.000 abstract 1
- -1 4-cyanophenoxy Chemical group 0.000 abstract 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 abstract 1
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 206010033557 Palpitations Diseases 0.000 abstract 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000001746 atrial effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Composición farmacéutica de liberación modificada que comprende 4-({3-[7-(3,3-dimetil-2-oxobutil)-9-oxa-3,7-diazabiciclo-[3.3.1]non-3-il]propil}amino)benzonitrilo, 2-{7-[3-(4-ciano-anilino)propil]-9-oxa-3,7-diazabiciclo [3.3.1]non-3-il}etilcarbamato de ter-butilo, 2-{7-[4-(4-cianofenil)butil]-9-oxa-3,7-diazabiciclo[3.3.1]non-3-il}etilcarbamato de ter-butilo o 2-{7-[(2S)-3-(4-cianofenoxi)-2-hidroxipropil]-9-oxa-3,7-diazabiciclo[3.3-1[}etilcarbamato de ter-butilo o una sal farmacéuticamente aceptable de cualquiera de estos compuestos, en particular una composición de liberación modificada de matriz polimérica gelificante. También se dan a conocer el procedimiento para su preparación y el uso de esta composición para la manufactura de un medicamento. Las composiciones son útiles para la profilaxis y/o tratamiento de arritmias cardíacas como por ejemplo, arritmia atrial, arritmia ventricular, fibrilación atrial y palpitación atrial.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0101326A SE0101326D0 (sv) | 2001-04-12 | 2001-04-12 | Pharmaceutical formulation |
| SE0101325A SE0101325D0 (sv) | 2001-04-12 | 2001-04-12 | Pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035807A1 true AR035807A1 (es) | 2004-07-14 |
Family
ID=26655442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101188A AR035807A1 (es) | 2001-04-12 | 2002-04-02 | Composicion farmaceutica de liberacion modificada apropiada para compuestos antiarritmicos, procedimiento para su preparacion, y uso de esta composicion para la manufactura de un medicamento para ser usado en la profilaxis o tratamiento de una arritmia |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20040132798A1 (es) |
| EP (1) | EP1389211A1 (es) |
| JP (1) | JP2004525969A (es) |
| KR (1) | KR20040005917A (es) |
| CN (1) | CN1279916C (es) |
| AR (1) | AR035807A1 (es) |
| BG (1) | BG108235A (es) |
| BR (1) | BR0208830A (es) |
| CA (1) | CA2443464A1 (es) |
| CZ (1) | CZ20032759A3 (es) |
| EE (1) | EE200300506A (es) |
| HU (1) | HUP0303481A3 (es) |
| IL (1) | IL158035A0 (es) |
| IS (1) | IS6990A (es) |
| MX (1) | MXPA03009213A (es) |
| MY (1) | MY141595A (es) |
| NO (1) | NO20034528L (es) |
| NZ (1) | NZ528559A (es) |
| PL (1) | PL367182A1 (es) |
| RU (1) | RU2003129229A (es) |
| SK (1) | SK12542003A3 (es) |
| TW (1) | TWI259836B (es) |
| WO (1) | WO2002083687A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US20060134210A1 (en) * | 2004-12-22 | 2006-06-22 | Astrazeneca Ab | Solid dosage form comprising proton pump inhibitor and suspension made thereof |
| KR20070100820A (ko) | 2005-01-31 | 2007-10-11 | 가부시키가이샤 바이오세렌택 | 경피 흡수 제제, 경피 흡수 제제 유지 시트 및 경피 흡수제제 유지 용구 |
| EP1893619A1 (en) | 2005-06-13 | 2008-03-05 | AstraZeneca AB | New oxabispidine compounds for the treatment of cardiac arrhytmias |
| TW200940110A (en) * | 2008-02-22 | 2009-10-01 | Astrazeneca Ab | Pharmaceutical formulation comprising oxabispidines |
| US10702485B2 (en) | 2011-07-09 | 2020-07-07 | Syntrix Biosystems Inc. | Compositions and methods for overcoming resistance to tramadol |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3732094A1 (de) * | 1987-09-24 | 1989-04-06 | Basf Ag | Bispidinderivate als klasse iii-antiarrhythmika |
| US5110933A (en) * | 1989-11-13 | 1992-05-05 | Board Of Regents Of Oklahoma State University | Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof |
| DE4402933A1 (de) * | 1994-02-01 | 1995-08-03 | Kali Chemie Pharma Gmbh | Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel |
| SE9704709D0 (sv) * | 1997-12-17 | 1997-12-17 | Astra Ab | Pharmaceutically active compounds |
| US6492355B1 (en) * | 1999-04-09 | 2002-12-10 | Astrazeneca Ab | Adamantane derivatives |
| SE9903759D0 (sv) * | 1999-10-18 | 1999-10-18 | Astra Ab | Pharmaceutically active compounds |
| SE0101329D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Pharmaceutical formulation |
| SE0101327D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New crystalline forms |
-
2002
- 2002-04-01 TW TW091106494A patent/TWI259836B/zh not_active IP Right Cessation
- 2002-04-02 AR ARP020101188A patent/AR035807A1/es not_active Application Discontinuation
- 2002-04-10 MY MYPI20021315A patent/MY141595A/en unknown
- 2002-04-12 IL IL15803502A patent/IL158035A0/xx unknown
- 2002-04-12 NZ NZ528559A patent/NZ528559A/en unknown
- 2002-04-12 RU RU2003129229/04A patent/RU2003129229A/ru not_active Application Discontinuation
- 2002-04-12 US US10/474,591 patent/US20040132798A1/en not_active Abandoned
- 2002-04-12 MX MXPA03009213A patent/MXPA03009213A/es unknown
- 2002-04-12 WO PCT/SE2002/000724 patent/WO2002083687A1/en not_active Ceased
- 2002-04-12 EE EEP200300506A patent/EE200300506A/xx unknown
- 2002-04-12 BR BR0208830-4A patent/BR0208830A/pt not_active IP Right Cessation
- 2002-04-12 PL PL02367182A patent/PL367182A1/xx unknown
- 2002-04-12 CZ CZ20032759A patent/CZ20032759A3/cs unknown
- 2002-04-12 JP JP2002581442A patent/JP2004525969A/ja not_active Withdrawn
- 2002-04-12 SK SK1254-2003A patent/SK12542003A3/sk unknown
- 2002-04-12 CN CNB028116348A patent/CN1279916C/zh not_active Expired - Fee Related
- 2002-04-12 CA CA002443464A patent/CA2443464A1/en not_active Abandoned
- 2002-04-12 KR KR10-2003-7013419A patent/KR20040005917A/ko not_active Withdrawn
- 2002-04-12 HU HU0303481A patent/HUP0303481A3/hu unknown
- 2002-04-12 EP EP02723010A patent/EP1389211A1/en not_active Withdrawn
-
2003
- 2003-10-06 BG BG108235A patent/BG108235A/bg unknown
- 2003-10-09 NO NO20034528A patent/NO20034528L/no not_active Application Discontinuation
- 2003-10-10 IS IS6990A patent/IS6990A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1514838A (zh) | 2004-07-21 |
| CA2443464A1 (en) | 2002-10-24 |
| IL158035A0 (en) | 2004-03-28 |
| BG108235A (bg) | 2005-04-30 |
| NO20034528L (no) | 2003-12-08 |
| US20040132798A1 (en) | 2004-07-08 |
| EE200300506A (et) | 2004-02-16 |
| CN1279916C (zh) | 2006-10-18 |
| RU2003129229A (ru) | 2005-04-10 |
| KR20040005917A (ko) | 2004-01-16 |
| WO2002083687A1 (en) | 2002-10-24 |
| MY141595A (en) | 2010-05-14 |
| SK12542003A3 (sk) | 2004-03-02 |
| IS6990A (is) | 2003-10-10 |
| HUP0303481A2 (hu) | 2004-01-28 |
| BR0208830A (pt) | 2004-03-09 |
| PL367182A1 (en) | 2005-02-21 |
| NZ528559A (en) | 2005-03-24 |
| MXPA03009213A (es) | 2004-01-29 |
| TWI259836B (en) | 2006-08-11 |
| EP1389211A1 (en) | 2004-02-18 |
| HUP0303481A3 (en) | 2005-04-28 |
| JP2004525969A (ja) | 2004-08-26 |
| NO20034528D0 (no) | 2003-10-09 |
| CZ20032759A3 (cs) | 2004-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2754573T3 (es) | Formulación de comprimido recubierto y método | |
| AR026064A1 (es) | Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios. | |
| JP3235847B2 (ja) | インプラント可能な骨代替材料 | |
| JP3553083B2 (ja) | 末梢性活性抗痛覚過敏オピエート | |
| PE20061046A1 (es) | Composicion farmaceutica que comprende telmisartan y amlodipino | |
| CZ309247B6 (cs) | 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru | |
| JP2004520290A5 (es) | ||
| BR0316082A (pt) | Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit | |
| WO2005035742A3 (en) | Methods of preparing and using stem cell compositions and kits comprising the same | |
| BR9807950A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto | |
| AR035807A1 (es) | Composicion farmaceutica de liberacion modificada apropiada para compuestos antiarritmicos, procedimiento para su preparacion, y uso de esta composicion para la manufactura de un medicamento para ser usado en la profilaxis o tratamiento de una arritmia | |
| CN110337304A (zh) | 神经调节蛋白预防、治疗或延迟室性心律失常的用途及其组合物 | |
| HUP0400069A2 (hu) | Gyógyászati kombinációk és alkalmazásuk a trómbózis megelőzésére és kezelésére | |
| ES2139673T3 (es) | Utilizacion de norastemizol para el tratamiento de rinitis alergica. | |
| BR0315316A (pt) | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit | |
| AR033658A1 (es) | Kit de componentes, metodo para el tratamiento de la trombosis,uso de un antagonista del receptor p2t en la elaboracion de un kit de componentes para el tratamiento de la trombosis, formulacion farmaceutica, uso de la formulacion farmaceutica en la elaboracion de un medicamento para el tratamiento d | |
| AR035806A1 (es) | Formulacion farmaceutica de liberacion inmediata apropiada para compuestos antiarritmicos, procedimiento para su preparacion, composicion farmaceutica solida, composicion liofilizada, uso de la formulacion o la composicion para la manufactura de un medicamento para ser usado en la profilaxis o trata | |
| EE200300364A (et) | 3,7-diasabitsüklo[3,3,0]oktaanid ja nende kasutamine südame arütmiate ravis | |
| BR0114366A (pt) | Composto, formulação farmacêutica, uso de um composto, método de profilaxia ou tratamento de uma arritimia e processo para a preparação de um composto | |
| BRPI0515261A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo | |
| MXPA03000439A (es) | Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida. | |
| UY28535A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
| BR0315609A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica | |
| MX9304197A (es) | Nuevo uso de dimero de lisozina y composiciones que lo contienen. | |
| BRPI0512012A (pt) | composto ou um derivado farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de profilaxia ou tratamento de uma arritmia, e, processo para a preparação de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |